Argenta and Zafgen in obesity drug discovery accord

The UK's Argenta Discovery, the contract research and respiratory R&D company, and Zafgen, a private, venture-backed US biopharmaceutical  company focused on developing novel obesity therapeutics, have entered  into a major drug discovery collaboration. Under the terms of the  agreement, financial terms of which were not disclosed, scientists from  the two companies will exploit Argenta's expertise in computer-aided  drug design, medicinal chemistry, assay development, in vitro screening,  drug metabolism and pharmacokinetics to accelerate development candidate  nomination for one of Zafgen's innovative therapeutics programs for  obesity.